This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ExpressGraft

Mallinckrodt plc

Drug Names(s): ExpressGraft

Description: ExpressGraft skin substitute is a living, cell-based tissue with the physical, chemical and histological characteristics of human skin. When applied topically to non-healing ulcers, this tissue provides immediate wound closure and is expected to be gradually replaced by the patient’s own cells during the wound healing process. The tissue’s ability to produce a potent immune system protein enables it to actively fight infections that routinely develop at the site of diabetic foot ulcers.

Deal Structure: Mallinckrodt and Stratatech
In August 2016, Mallinckrodt announced that it has entered into a merger agreement with Stratatech Corporation. Financial terms of the transaction were not disclosed.

In September 2016, Mallinckrodt announced it closed the acquisition of Stratatech Corporation.


ExpressGraft News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug